公司資料
Revolution Medicines 股價、新聞與催化劑
- 股票代碼:
- RVMD
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
212.00 USD (+4.07%)
收盤價
最後更新: 2026年8月17日
32.2B USD
市值
股價為何變動
As of Aug 17, 2026, RVMD closed up 4.07% at $212.00. No new same-company headline was identified in the current news window.
公司概覽
RAS(ON) Inhibitors
Revolution Medicines develops oral targeted therapies that bind active, GTP-loaded RAS proteins. Its portfolio covers multiple RAS mutations and combination strategies across pancreatic and lung cancers.
Daraxonrasib
Daraxonrasib is a multi-selective RAS(ON) inhibitor and the company's lead late-stage asset. It has demonstrated Phase 3 survival benefit in previously treated metastatic pancreatic cancer.
Pancreatic-Cancer Franchise
Beyond second-line disease, RASolute 304 evaluates daraxonrasib in resectable pancreatic cancer after surgery, while another registrational program addresses first-line metastatic disease.
Zoldonrasib
Zoldonrasib selectively targets RAS G12D and is being developed in lung cancer as monotherapy, with standard of care and in an inhibitor-doublet combination with daraxonrasib.
Elironrasib
Elironrasib is a covalent RAS G12C-selective inhibitor. Revolution Medicines is defining its registrational strategy within a broader mutation-specific portfolio.
Lung-Cancer Development
RASolve 301 evaluates daraxonrasib in previously treated non-small cell lung cancer, while RASolve 308 is a planned first-line Phase 3 study of zoldonrasib plus standard therapy.
未來催化劑
- Detailed Phase 3 RASolute 302 results at an ASCO 2026 plenary session.
- Global regulatory submissions, including a U.S. NDA, for daraxonrasib in previously treated pancreatic cancer.
- Initiation of the Phase 3 RASolve 308 study in the first half of 2026.
- Substantial completion of enrollment in RASolve 301 during 2026.
- Initiation of a registrational zoldonrasib-plus-daraxonrasib study in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。